We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago.
- Authors
Chon, W. James; Kadambi, Pradeep V.; Xu, Chang; Becker, Yolanda T.; Witkowski, Piotr; Pursell, Kenneth; Kane, Brenna; Josephson, Michelle a.
- Abstract
Introduction: Although antiviral prophylaxis for cytomegalovirus (CMV) is widely used, CMV infection remains common in renal transplant recipients with adverse consequences. Methods: We report 5 cases of renal transplant recipients with resistant CMV infection who were successfully managed with leflunomide at the University of Chicago Medical Center. Results: Five renal transplant recipients (2 simultaneous pancreas/kidney transplants, 3 deceased donor kidney transplants) were diagnosed with GCV-resistant CMV infection from 2003 to 2011. Of the 4 patients who had resistance genotype testing, 3 showed a UL97 mutation and 1 patient had a clinically resistant CMV infection. All patients received CMV prophylaxis with valganciclovir for 3 months. The number of days from the date of transplant to viremia ranged from 38 to 458 days (median 219). All 5 patients received other antiviral agents (e.g. ganciclovir, foscarnet), and in 4 patients, viremia was cleared before leflunomide was initiated as consolidation (or maintenance) therapy. Conclusion: Leflunomide was well tolerated and successful in preventing recurrence of viremia in renal transplant recipients with resistant CMV infection. The beneficial effect of leflunomide in this setting warrants further investigation. © 2015 S. Karger AG, Basel
- Publication
Case Reports in Nephrology & Dialysis, 2015, Vol 5, Issue 1, p96
- ISSN
2296-9705
- Publication type
Article
- DOI
10.1159/000381470